Diagnosis and classification of idiopathic inflammatory myopathies

Journal of Internal Medicine

Volumn 280, Issue 1, 2016, Pages 39-51

  Lundberg, I E ^a   Miller, F W ^b   Tjarnlund A ^a   Bottai, M ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

criteria; dermatomyositis; idiopathic inflammatory myopathy; inclusion body myositis; polymyositis

Indexed keywords

AUTOANTIBODY; MYOSITIS SPECIFIC AUTOANTIBODY; UNCLASSIFIED DRUG;

ANTISYNTHETASE SYNDROME; DERMATOMYOSITIS; DISEASE CLASSIFICATION; HUMAN; INTERSTITIAL LUNG DISEASE; MUSCLE BIOPSY; MYOSITIS; PHENOTYPE; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW;

EID: 84975165592     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12524     Document Type: Review

References (30)

1. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med 1991; 325: 1487–98.
2. Betteridge Z, McHugh N. Myositis specific autoantibodies - an important tool to support diagnosis of myositis. J Int Med 2016; 280: 8–23.
3. Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep 2014; 16: 465.
4. Basharat P, Christopher-Stine L. Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management. Curr Rheumatol Rep 2015; 17: 72.
5. Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P. Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991; 18: 1693–700.
6. Lampa J, Nennesmo I, Einarsdottir H, Lundberg I. MRI guided muscle biopsy confirmed polymyositis diagnosis in a patient with interstitial lung disease. Ann Rheumatol Dis 2001; 60: 423–6.
7. Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum 2007; 56: 2729–39.
8. Albrecht I, Wick C, Hallgren Å, Tjärnlund A, Nagaraju K, Andrade FT, et al. Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest 2015; 125: 4612–24 d9.
9. Ghirardello A, Rampudda M, Ekholm L, Bassi N, Tarricone E, Zampieri SZ, et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 2010; 49: 2370–4.
10. Pluk H, van Hoeve BJ, van Dooren SH, Stammen-Vogelzangs J, van der Heijden A, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol 2013; 73: 397–407.
11. Larman HB, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013; 73: 408–18.
12. Diederichsen LP, Simonsen JA, Diederichsen AC, Kim WY, Hvidsten S, Hougaard M, et al. Cardiac abnormalities assessed by non-invasive techniques in patients with newly diagnosed idiopathic inflammatory myopathies. Clin Exp Rheumatol 2015; 33: 706–14.
13. Hilton-Jones D, Brady S. Diagnostic criteria for inclusion body myositis. J Int Med 2016; 280: 52–62.
14. Medsger TA, Dawson WN, Masi AT. The epidemiology of polymyositis. Am J Med 1970; 48: 715–23.
15. DeVere R, Bradley WG. Polymyositis: its presentation, morbidity and mortality. Brain 1975; 98: 637–66.
16. Bohan A, Peter JB. Polymyositis and dermatomyositis (parts 1 and 2). New Engl J Med 1975; 292: 344–7,-403-7.
17. Bohan A, Peter JB, Bowman RL, Pearson CM. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 255–86.
18. Oddis CV, Medsger TA Jr. Inflammatory myopathies. Baillieres Clin Rheumatol 1995; 9: 497–514.
19. Tanimoto K, Nakano K, Kano S, Mori S, Ueki H, Nishitani H, et al. Classification criteria for polymyositis and dermatomyositis. J Rheumatol 1995; 22: 668–74.
20. Targoff IN, Miller FW, Medsger TA Jr, Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol 1997; 9: 527–35.
21. Griggs RC, Askanas V, DiMauro S et al. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705–13.
22. van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61: 316–21.
23. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971–82.
24. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14: 337–45.
25. Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013; 31: 767–9.
26. Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52: 2607–15.
27. Miller FW, Rider LG, Chung Y-L, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatol 2001; 11: 1262–73.
28. Tjärnlund A, Bottai M, Rider LG, Werth VP, Pilkington CA, de Visser M. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. ACR/ARHP annual meeting abstract supplement. Arthritis Rheum, 2014; 66: S1–1402 doi: 10.1002/art.38914.
29. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 2014; 13: 367–71.
30. Dugan EM, Huber AM, Miller FW, Rider LG; International Myositis Assessment and Clinical Studies Group. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol Online J 2009; 15: 1.